Research Analysts Set Expectations for Cryoport Q1 Earnings

Cryoport, Inc. (NASDAQ:CYRX) – Investment analysts at Roth Capital cut their Q1 2025 earnings per share (EPS) estimates for shares of Cryoport in a research note issued on Wednesday, March 5th. Roth Capital analyst R. Baldry now forecasts that the company will earn ($0.34) per share for the quarter, down from their prior forecast of ($0.32). The consensus estimate for Cryoport’s current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Cryoport’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.30) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.29) EPS.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The firm had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter in the previous year, the company posted ($0.29) EPS.

Several other research analysts also recently weighed in on the company. Guggenheim initiated coverage on Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. Roth Mkm cut their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Cryoport in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Cryoport currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.29.

Cryoport Stock Up 0.8 %

CYRX stock opened at $6.66 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The company has a market capitalization of $329.21 million, a price-to-earnings ratio of -1.97 and a beta of 1.59. Cryoport has a fifty-two week low of $4.58 and a fifty-two week high of $20.10. The stock has a fifty day moving average of $7.31 and a 200-day moving average of $7.62.

Institutional Trading of Cryoport

Institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. lifted its holdings in Cryoport by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Cryoport during the 4th quarter valued at about $51,000. Avanza Fonder AB purchased a new position in shares of Cryoport during the fourth quarter worth about $64,000. Quarry LP bought a new position in shares of Cryoport in the fourth quarter worth approximately $69,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Cryoport in the third quarter valued at approximately $82,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.